Dean Schorno

Director of Finance/CFO at RIGEL PHARMACEUTICALS, INC.

Net worth: 4 M $ as of 2026-08-30

63 year

64 connections

Health Technology

Consumer Services

Health Services

Profile

Dean L.
Schorno is Chief Financial Officer & Executive Vice President at Rigel Pharmaceuticals, Inc. since 2018.
Formerly, Mr. Schorno was Chief Financial Officer & Head-Investor Relations at Genomic Health, Inc. from 2011 to 2014, Chief Financial Officer at Adaptive Biotechnologies Corp.
from 2014 to 2015, and Chief Financial Officer & Head-Operations at 23andMe, Inc. from 2015 to 2018.
Education includes graduate studies at Golden Gate University and undergraduate studies at the University of California, Berkeley.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
RIGEL PHARMACEUTICALS, INC. 0.45%	2026-09-01	83,462 ( 0.45% )	4 M $	2026-08-30

Dean Schorno active positions

Companies	Position	Start
RIGEL PHARMACEUTICALS, INC.	Director of Finance/CFO	2018-05-28

All active positions of Dean Schorno

Former positions of Dean Schorno

Companies	Position	End
23andMe, Inc. 23andMe, Inc. Medical SpecialtiesHealth Technology Develops DNA analysis test kits	Director of Finance/CFO	2018-04-30
ADAPTIVE BIOTECHNOLOGIES CORPORATION	Director of Finance/CFO	2015-08-09
GENOMIC HEALTH, INC.	Director of Finance/CFO	2014-06-30

See the detail of Dean Schorno's experience

Training of Dean Schorno

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Dean Schorno's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	6
Rigel Pharmaceuticals, Inc. Rigel Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which discovers, develops and provides novel small-molecule drugs	Health Technology
Genomic Health, Inc. Genomic Health, Inc. Medical/Nursing ServicesHealth Services Engages in genomic-based diagnostic tests for overtreatment and optimal treatment of early stage cancer	Health Services
Golden Gate University Golden Gate University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of California, Berkeley University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
23andMe, Inc. 23andMe, Inc. Medical SpecialtiesHealth Technology Develops DNA analysis test kits	Health Technology
Adaptive Biotechnologies Corp. Adaptive Biotechnologies Corp. BiotechnologyHealth Technology Develops minimal residual disease and immune medicine	Health Technology